Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pharmacogenomics And Hypertension: Current Insights

Full text
Author(s):
Oliveira-Paula, Gustavo H. [1, 2] ; Pereira, Sherliane C. [1] ; Tanus-Santos, Jose E. [1] ; Lacchini, Riccardo [3]
Total Authors: 4
Affiliation:
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Ribeirao Preto, SP - Brazil
[2] Albert Einstein Coll Med, Wilf Family Cardiovasc Res Inst, Dept Med, Div Cardiol, New York, NY - USA
[3] Univ Sao Paulo, Ribeirao Preto Coll Nursing, Dept Psychiat Nursing & Human Sci, Av Bandeirantes 3900, BR-14040902 Ribeirao Preto, SP - Brazil
Total Affiliations: 3
Document type: Review article
Source: PHARMACOGENOMICS & PERSONALIZED MEDICINE; v. 12, p. 341-359, 2019.
Web of Science Citations: 0
Abstract

Hypertension is a multifactorial disease that affects approximately one billion subjects worldwide and is a major risk factor associated with cardiovascular events, including coronary heart disease and cerebrovascular accidents. Therefore, adequate blood pressure control is important to prevent these events, reducing premature mortality and disability. However, only one third of patients have the effective control of blood pressure, despite several classes of antihypertensive drugs available. These disappointing outcomes may be at least in part explained by interpatient variability in drug response due to genetic polymorphisms. To address the effects of genetic polymorphisms on blood pressure responses to the antihypertensive drug classes, studies have applied candidate genes and genome wide approaches. More recently, a third approach that considers gene-gene interactions has also been applied in hypertension pharmacogenomics. In this article, we carried out a comprehensive review of recent findings on the pharmacogenomics of antihypertensive drugs, including diuretics, beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, and calcium channel blockers. We also discuss the limitations and inconsistences that have been found in hypertension pharmacogenomics and the challenges to implement this valuable approach in clinical practice. (AU)

FAPESP's process: 18/18312-2 - EVALUATION OF THE EPIGENETIC EFFECTS OF ATORVASTATIN ON THE REGULATION OF EXPRESSION OF GENES RELATED TO NITRIC OXIDE IN EXPERIMENTAL HYPERTENSION MODEL
Grantee:Riccardo Lacchini
Support type: Regular Research Grants